Sign up
Pharma Capital

VentriPoint Diagnostics to showcase its VMS Plus heart system at Milan conference

The event has nearly 4,000 healthcare professionals from over 90 countries around the world
1543500986_shutterstock_657615100.jpg
Ventripoint is a heart imaging tech group

Medtech group VentriPoint Diagnostics Ltd (CVE:VPT) will showcase its next-generation VMS Plus heart imaging system at EuroEcho 2018 in Milan.

With nearly 4,000 healthcare professionals from over 90 countries around the world, EuroEcho is one of the world's largest cardiovascular imaging congress.

READ: VentriPoint Diagnostics reports that its new approved heart technology being used by internationally renowned pediatric cardiologist

"We are excited to showcase our next-generation VMS+ System to the European market. We will have live scanning in the booth to provide the opportunity for hands-on use by the cardiology community," said Mehran Mehrtash, the vice-president, the worldwide distributor of sales at VentriPoint.

The next-generation system is designed to use Artificial Intelligence (AI) to assess the performance of all four chambers of the heart from standard 2D echo images.

Artificial Intelligence (AI) is the future of cardiac imaging and is transforming clinical outcomes, says the company.

The conference is in Milan, Italy and runs from December 5 to 7, providing hands-on demonstrations of the next-generation VMS+ System.

Contact Giles Gwinnett at [email protected]

Follow Giles on Twitter @Gile74

Giles_55af4ddca6481.jpg


Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.